| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | C3 binding protein; C3b/C4b receptor; C3BR; C4BR; CD35; CR1; KN;;CR1 |
| WB Predicted band size | Calculated MW: 224 kDa ; Observed MW: 280 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human CR1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇与CD35(CR1)抗体相关的参考文献示例(内容为虚构概括，供参考)：
1. **文献名称**：*CD35 Antibody Targeting Modulates Immune Complex Clearance in Autoimmunity*
**作者**：Smith J, et al.
**摘要**：研究CD35抗体在小鼠系统性红斑狼疮(SLE)模型中的作用，发现阻断CD35可减少免疫复合物沉积，缓解肾小球肾炎，提示其作为自身免疫病治疗的潜在靶点。
2. **文献名称**：*CR1 Expression on Erythrocytes and Its Role in Malaria Pathogenesis*
**作者**：Chen L, et al.
**摘要**：通过抗CD35抗体分析疟疾患者红细胞表面CR1水平，发现CR1表达降低与疟原虫感染加重相关，揭示CD35在宿主防御中的关键作用。
3. **文献名称**：*CD35 as a Biomarker for B-cell Lymphoma Subtyping*
**作者**：Wang H, et al.
**摘要**：利用CD35单克隆抗体进行流式细胞术分析，发现其在特定B细胞淋巴瘤亚型中高表达，为临床诊断和分型提供新依据。
4. **文献名称**：*Anti-CD35 Antibody Enhances Complement-Mediated Tumor Cell Lysis*
**作者**：Gomez R, et al.
**摘要**：体外实验显示，抗CD35抗体可协同补体系统增强对肿瘤细胞的杀伤效果，提示其在癌症免疫治疗中的潜在应用价值。
(注：以上内容为模拟生成，实际文献需通过PubMed等数据库检索。)
CD35. also known as complement receptor type 1 (CR1), is a transmembrane glycoprotein expressed on erythrocytes, B cells, neutrophils, and follicular dendritic cells. It plays a critical role in immune complex clearance, regulation of complement activation, and modulation of cellular immune responses. CD35 binds complement components C3b and C4b, facilitating the removal of opsonized pathogens and immune complexes from circulation. Dysregulation of CD35 has been linked to autoimmune diseases, infections, and cancer progression.
CD35 antibodies are tools used to study the receptor’s expression, function, and interactions. Monoclonal antibodies against CD35 (e.g., clones E11. J3D3) are widely employed in flow cytometry, immunohistochemistry, and functional assays to characterize immune cells or analyze CR1-mediated processes. Polyclonal antibodies are also utilized for broader epitope recognition in research settings. Clinically, CD35 antibodies have potential diagnostic applications in evaluating immune disorders or malignancies marked by altered CR1 expression. Therapeutic strategies exploring CD35-targeting antibodies are emerging, particularly in modulating complement activity in autoimmune diseases or enhancing phagocytosis in cancer immunotherapy. However, challenges remain in balancing specificity and minimizing off-target effects due to CD35’s broad tissue distribution and complex ligand interactions. Ongoing research continues to refine antibody designs to harness CD35’s regulatory functions for therapeutic benefit.
×
